Open AccessMoxonidin in combined therapy of metabolic syndrome
Author(s) -
В. И. Подзолков,
Е. А. Гладышева,
А. Е. Брагина
Publication year - 2007
Publication title -
arterialʹnaâ gipertenziâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-8524
pISSN - 1607-419X
DOI - 10.18705/1607-419x-2007-13-4-246-249
Subject(s) - moxonidine , fenofibrate , metabolic syndrome , imidazoline receptor , uric acid , medicine , agonist , endocrinology , pharmacology , combination therapy , obesity , receptor
The paper presents the results of 24-weeks follow-up and treatment patients with metabolic syndrome.It shows antihypertensive effect of imidazoline-receptor agonist moxonidine and hypolipidemic effect of micronized fenofibrate in patients with metabolic syndrome. The combination demonstrate synergic action on carbohydrate and uric acid metabolism. Thus, it can significantly decrease the level of cardio-vascular risk (SCORE) in patients with metabolic syndrome.